-+ 0.00%
-+ 0.00%
-+ 0.00%

Jury finds Lilly breaches implied covenant in rezpegaldesleukin license, awards Nektar USD 90 million plus interest

PUBT·09/25/2026 11:01:55
Listen to the news
Jury finds Lilly breaches implied covenant in rezpegaldesleukin license, awards Nektar USD 90 million plus interest
  • A U.S. jury found Lilly breached the implied covenant of good faith in a rezpegaldesleukin license agreement with Nektar Therapeutics.
  • The verdict followed a jury trial that began Sept. 8, 2026 in federal court in Northern California.
  • Damages were set at USD 90 million, with interest to be determined by the court.
  • Post-trial motions remain pending. Any final judgment could face appeal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-103215), on September 25, 2026, and is solely responsible for the information contained therein.